On October 20, Bitcoin's price showed mixed technical signals, trading below a daily ascending trendline but above the 50-day moving average. Short-term indicators on the four-hour chart suggested a possible downside break, although no clear breakout occurred. The weekly chart indicated the broader trend remains upward unless Bitcoin closes below a key support level. Market conditions include inflation concerns, rising bond yields, oil prices, a strong dollar, weaker U.S. stocks, and profit-taking in AI-related stocks, all contributing to uncertainty in Bitcoin's near-term direction.
Bitcoin technical analysis on Oct. 20 offers context for cryptocurrency markets. For readers following major cryptocurrencies, here is Pluang's market snapshot as of Oct 21, 2026 06:12 WIB: 45 of 50 major cryptocurrencies rose today. Notable movers include MANA at Rp1.583 (+5.67%, 87% Sell), CRV at Rp7.007 (+5.42%, 96% Sell), and SNX at Rp4.060 (+4.96%, 25% Sell).
Medical Informatics Corp. has launched the Sickbay Experience Demo Center at Texas Medical Center's Helix Park, showcasing its FDA-cleared Sickbay platform. This interactive center demonstrates how real-time patient data from various medical devices ...
Grupo Aeroportuario del Pacífico reported Q3 2026 earnings per share of $2.66 and revenue of $632.9 million, both below analyst expectations. Despite the miss, the company saw a 13.2% rise in revenue excluding construction services and a 19.2% increa...
Northern Trust is set to report its Q3 2026 earnings with analysts forecasting a 24.9% rise in earnings per share to $2.86 and an 11.8% increase in revenue to $2.26 billion. Growth is driven by an 11.4% increase in net interest income and a 12.1% ris...
Moody's is expected to report Q3 2026 earnings of around $4.25 per share on revenue near $2.08 billion, driven by steady demand for credit ratings and growth in Moody's Analytics, especially from recurring subscriptions and AI tools. While Moody's In...
Raymond James increased its price target for Rapport Therapeutics to $86 following positive Phase 2 trial results of RAP-219, a drug treating acute bipolar mania. The trial showed statistically significant improvement in patients and a favorable safe...
